Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder

Recent clinical trials indicate that pharmacogenetic-guided treatment of major depressive disorder (MDD) results in higher treatment response rates by genetically matching patients to medications and avoiding a trial-and-error process. To evaluate the cost-effectiveness of a pharmacogenetic test (ID...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of managed care & specialty pharmacy 2018-08, Vol.24 (8), p.726-734
Hauptverfasser:	Groessl, Erik J, Tally, Steven R, Hillery, Naomi, Maciel, Alejandra, Garces, Jorge A
Format:	Artikel
Sprache:	eng
Schlagworte:	Antidepressive Agents - economics Antidepressive Agents - pharmacology Antidepressive Agents - therapeutic use Cost Savings - statistics & numerical data Cost-Benefit Analysis Depressive Disorder, Major - diagnosis Depressive Disorder, Major - drug therapy Depressive Disorder, Major - genetics Depressive Disorder, Major - mortality Health Care Costs - statistics & numerical data Humans Markov Chains Middle Aged Models, Economic Pharmacogenomic Testing - economics Pharmacogenomic Testing - methods Pharmacogenomic Variants - genetics Precision Medicine - economics Precision Medicine - methods Quality of Life Quality-Adjusted Life Years Randomized Controlled Trials as Topic Severity of Illness Index Suicide - psychology Suicide - statistics & numerical data Survival Rate Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!